First Trust Advisors LP boosted its position in Pfizer Inc. (NYSE:PFE) by 21.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,693,523 shares of the biopharmaceutical company’s stock after buying an additional 664,585 shares during the period. Pfizer accounts for 0.4% of First Trust Advisors LP’s holdings, making the stock its 28th largest position. First Trust Advisors LP owned 0.06% of Pfizer worth $130,049,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. BlackRock Fund Advisors raised its position in shares of Pfizer by 1.5% in the first quarter. BlackRock Fund Advisors now owns 92,489,121 shares of the biopharmaceutical company’s stock worth $2,741,378,000 after buying an additional 1,403,646 shares during the period. Wellington Management Group LLP raised its position in shares of Pfizer by 5.0% in the first quarter. Wellington Management Group LLP now owns 82,813,816 shares of the biopharmaceutical company’s stock worth $2,454,601,000 after buying an additional 3,936,078 shares during the period. Franklin Resources Inc. raised its position in shares of Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock worth $1,864,446,000 after buying an additional 9,005,107 shares during the period. BlackRock Group LTD raised its position in shares of Pfizer by 5.6% in the first quarter. BlackRock Group LTD now owns 59,474,971 shares of the biopharmaceutical company’s stock worth $1,762,838,000 after buying an additional 3,154,116 shares during the period. Finally, Legal & General Group Plc raised its position in shares of Pfizer by 1.7% in the first quarter. Legal & General Group Plc now owns 29,385,795 shares of the biopharmaceutical company’s stock worth $871,079,000 after buying an additional 488,194 shares during the period. Institutional investors own 69.66% of the company’s stock.
Pfizer Inc. (NYSE:PFE) traded down 0.06% on Monday, hitting $32.64. The stock had a trading volume of 3,604,536 shares. The stock’s 50-day moving average is $34.02 and its 200-day moving average is $34.27. The company has a market cap of $197.98 billion, a P/E ratio of 28.94 and a beta of 0.86. Pfizer Inc. has a 52-week low of $28.25 and a 52-week high of $37.39.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The business earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. During the same period in the prior year, the business posted $0.56 earnings per share. The company’s revenue was up 10.9% on a year-over-year basis. Analysts expect that Pfizer Inc. will post $2.46 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be given a dividend of $0.30 per share. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 annualized dividend and a yield of 3.67%. Pfizer’s payout ratio is 95.24%.
PFE has been the topic of a number of recent research reports. Vetr upgraded Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 target price on the stock in a research note on Monday, June 27th. Deutsche Bank AG reiterated a “buy” rating and set a $44.00 target price on shares of Pfizer in a research note on Thursday, August 18th. Credit Suisse Group AG reiterated an “outperform” rating and set a $40.00 target price on shares of Pfizer in a research note on Monday, August 22nd. Piper Jaffray Cos. set a $54.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, August 23rd. Finally, Jefferies Group set a $41.50 price target on Pfizer and gave the stock a “buy” rating in a research report on Thursday, July 14th. Eleven research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $38.59.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.